Leerink Partnrs Has Pessimistic View of Hologic Q3 Earnings

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Research analysts at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for Hologic in a research report issued on Thursday, February 6th. Leerink Partnrs analyst P. Souda now expects that the medical equipment provider will post earnings per share of $1.10 for the quarter, down from their prior forecast of $1.12. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Hologic's current full-year earnings is $4.27 per share. Leerink Partnrs also issued estimates for Hologic's FY2025 earnings at $4.27 EPS, Q1 2026 earnings at $1.14 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.17 EPS, FY2026 earnings at $4.60 EPS and FY2027 earnings at $4.88 EPS.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%.

A number of other equities research analysts have also issued reports on HOLX. Royal Bank of Canada reduced their price target on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 6th. StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th. Needham & Company LLC downgraded Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price on the stock. in a research note on Monday, February 3rd. Raymond James restated an "outperform" rating and issued a $90.00 price target (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, Stephens restated an "overweight" rating and issued a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Ten investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $85.77.

Hologic Price Performance

Shares of Hologic stock traded down $0.77 on Friday, reaching $64.47. The company's stock had a trading volume of 1,084,524 shares, compared to its average volume of 2,548,522. The company has a quick ratio of 3.03, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic has a 52-week low of $63.62 and a 52-week high of $84.67. The company has a market capitalization of $14.55 billion, a P/E ratio of 20.30, a PEG ratio of 2.14 and a beta of 0.97. The stock has a 50-day moving average price of $72.06 and a 200-day moving average price of $77.67.

Institutional Investors Weigh In On Hologic

Several institutional investors and hedge funds have recently modified their holdings of HOLX. Wolff Wiese Magana LLC acquired a new position in shares of Hologic in the third quarter worth about $25,000. General Partner Inc. acquired a new stake in Hologic during the fourth quarter valued at approximately $26,000. Groupama Asset Managment raised its position in shares of Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC raised its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares during the period. Finally, First Horizon Advisors Inc. boosted its stake in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 134 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the company's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company's stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.88% of the stock is owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.